Company News
Avalo Therapeutics Shares Rise 35% on Trial
Avalo Therapeutics shares rose 35% after its Phase 2 LOTUS trial met primary HiSCR75 endpoint, showing 42% response versus 25.6% placebo.
The 253‑patient trial showed secondary gains on HiSCR50, IHS4
